Gainers
Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.
Not this again.
Masks and social distancing should be mandated or encouraged in public to protect people from possible “long COVID”, a new Department of Health and Human Services report